Development and analytical validation of a next-generation sequencing based microsatellite instabili

October 18, 2019

The assay has a clinically relevant five-day turnaround time and can be conducted on as little as 20 ng genomic DNA with a batch size of up to forty samples in a single run.

Assay performance with respect to accuracy, reproducibility, precision as well as control sample performance was estimated across a wide range of FFPE samples of multiple histologies to address pre-analytical variability, and analytical variability.

Dr. Sean T. Glenn from OmniSeq Inc., Buffalo, NY 14203, USA, the Center for Personalized Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA and the Department of Molecular and Cellular Biology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA said, "Microsatellite instability (MSI) is a well-described phenomenon characterized by the altered length of short repetitive regions of DNA referred to as microsatellites."

After amplification, fragment analysis chromatograms for each microsatellite are manually reviewed to assess differences between tumor and normal samples from the same patient in order to identify length differences, or so-called instability, in each microsatellite.

Although CRA and EEM account for the majority of microsatellite unstable tumors, microsatellite instability has a low but substantial incidence in various other tumors.

Consequently, the requirement of normal DNA can limit the number of patients that can have testing performed due to the difficulty to obtain normal tissue leading to suboptimal turnaround time or an inability to complete microsatellite testing.

Although there are additional published studies that use NGS testing to evaluate MSI status and those that use conventional fragment analysis without matched normal, the authors have developed the first agile NGS platform that is Clinical Laboratory Improvement Amendments certified and New York State Clinical Laboratory Evaluation Program approved for clinical MSI testing in patients using next-generation sequencing that can be utilized across all solid tumors without the need of matched normal tissue.

The Glenn Research team concluded, "Overall, we have developed the first NYS-CLEP approved, analytically validated MSI assay that requires minimum input of tumor DNA without the need for matched normal and is histology agnostic."
Full text -

Correspondence to - Sean T. Glenn -

Keywords - next-generation sequencing, NGS, microsatellite instability, MSI

About Oncotarget

Oncotarget is a weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

Oncotarget is published by Impact Journals LLC.

To learn more about Oncotarget, please visit

Media Contact

Impact Journals LLC

Related Microsatellite Articles from Brightsurf:

Stretches of repeating DNA predispose to systemic sclerosis
Researchers from the University of Tsukuba found that extended repeats of DNA in the gene FLI1 are associated with systemic sclerosis.

Genetically similar fungi cause severe infections in different hospitals
Present in the human digestive tract, species of Candida can cause bloodstream infections in patients treated in hospital intensive care units.

Artificial intelligence classifies colorectal cancer using IR imaging
Infrared microscopy can automatically detect the type of intestinal tumour within only 30 minutes.

Researchers study genetic outcomes of translocating bighorn sheep
Bighorn sheep have maintained a distinctive population genetic structure in Wyoming, even with historical population losses and translocations.

Immunotherapy prior to surgery is effective in colon cancer
Patients with colon cancer, but no distant metastases, can benefit from a short course of immunotherapy while waiting for their surgery, as it can cause tumours to shrink substantially or clear up in a very short time.

Development and analytical validation of a next-generation sequencing based microsatellite instabili
The assay has a clinically relevant 5-day turnaround time and can be conducted on as little as 20 ng genomic DNA with a batch size of up to forty samples in a single run.

A liquid biopsy test can identify patients who may respond to immune checkpoint blockade
A new liquid biopsy test could detect microsatellite instability (MSI) and tumor mutational burden (TMB), indicating that it could help determine which patients are likely to respond to immune checkpoint inhibitors.

MSI detection via liquid biopsy shows high concordance with results from tissue samples
Incorporation of pan-cancer microsatellite instability (MSI) detection into the 74-gene panel Guardant360 liquid biopsy assay showed high concordance with matched tissue samples in nearly 1,000 patients.

Mutational intensity influences a tumor's response to PD-1 immunotherapy
Following FDA approval last year of PD-1 immune checkpoint inhibitors for tumors with mismatch repair deficiency, a new study reveals more about why responses of these tumors to this immunotherapy vary, specifically implicating mutation intensity.

Biomarker may predict if immunotherapy is right choice for colorectal cancer patients
Foundational research could help metastatic colorectal cancer patients decide whether to choose immunotherapy or chemotherapy as a first treatment option.

Read More: Microsatellite News and Microsatellite Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to